PDF(Pubmed)
Abstract：
Introduction Combination antifungal regimens are frequently employed in the treatment of invasive fungal infections in patients who are immunocompromised, particularly for cancer and transplant patients. Terbinafine is a potential agent of interest for combination regimens. Methods We reviewed data over a six-year period examining patient outcomes in terms of both mortality and distribution of pathogens. The total number of patients in our study was 64. The use of terbinafine versus no terbinafine in combination therapy was assessed. Of the 64 patients analyzed, only 14 received terbinafine. Mortality was calculated for both groups, and demographics were analyzed by descriptive statistics. Results There was no statistical difference in mortality outcomes in either group. The addition of terbinafine was well tolerated and did not appear to result in any undue toxicity concerns. Discussion We wish to draw greater attention to this potential agent within our armamentarium for invasive fungal infections. To our knowledge, the total number of patients in our study, while small, represents the largest reported cohort in the literature to date. Sensitivities are crucial to be obtained for fungal pathogens as this likely undermined the utility of terbinafine in our study with larger than expected numbers of multidrug-resistant Fusarium. With limited patient numbers, a multicenter trial would be beneficial to further examine terbinafine in combination regimens.
摘要：
介绍联合抗真菌治疗方案经常用于治疗免疫功能低下患者的侵袭性真菌感染。特别是癌症和移植患者。特比萘芬是联合治疗方案的潜在药物。方法我们回顾了六年期间的数据，从死亡率和病原体分布方面检查了患者的预后。我们研究的患者总数为64。评估了在联合治疗中使用特比萘芬与不使用特比萘芬的情况。在分析的64名患者中，只有14人接受了特比萘芬。计算两组的死亡率，和人口统计学进行描述性统计分析。结果两组患者的死亡率无统计学差异。特比萘芬的加入具有良好的耐受性,并且似乎没有导致任何不适当的毒性问题。讨论我们希望在我们的医疗设备中引起更多的关注，以用于侵袭性真菌感染。据我们所知,我们研究中的患者总数，虽然小,代表迄今为止文献中报告的最大队列。获得真菌病原体的敏感性至关重要，因为这可能会破坏特比萘芬在我们研究中的效用，其多药耐药镰刀菌的数量超过预期。病人数量有限，多中心试验将有利于进一步检查特比萘芬的联合用药方案.
